Get started
Author

Margaretha G.M. Roemer

Observed names: M GM Roemer, M. G. M. Roemer, M. Roemer, M.G. Roemer, Margaretha G M Roemer, Margaretha G. M. Roemer, Margaretha G. Roemer, Margaretha GM Roemer, Margaretha Roemer, Margaretha G.M. Roemer, Roemer, M. G., Roemer, Margaretha Gesina Maria
Observed institutions: Brigham and Women's Hospital, Harvard University, University of Massachusetts Chan Medical School, Amsterdam UMC Location University of Amsterdam, The Netherlands Cancer Institute, University Medical Center Utrecht, Yale University, Noordwest Ziekenhuisgroep, Oncode Institute, Dana-Farber Cancer Institute, Stanford Medicine, Amsterdam University Medical Centers, Dana-Farber Brigham Cancer Center, Blood Cancer United, UMass Memorial Medical Center, Cancer Center Amsterdam, Vrije Universiteit Amsterdam, Amsterdam UMC Location Vrije Universiteit Amsterdam
ORCID: 0000-0003-0220-3496
Observed ORCID: 0000-0003-0220-3496
OpenAlex ID: A5013440190
Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes
2018 · Bjoern Chapuy, Chip Stewart, et al. · Nature Medicine · 1,936
Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial
2016 · Anas Younes, Armando Santoro, et al. · The Lancet Oncology · 927
PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies
2013 · Benjamin J. Chen, Bjoern Chapuy, et al. · Clinical Cancer Research · 844
PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome
2016 · Margaretha G.M. Roemer, Ranjana H. Advani, et al. · Journal of Clinical Oncology · 792
Discovery and Characterization of Super-Enhancer-Associated Dependencies in Diffuse Large B Cell Lymphoma
2013 · Bjoern Chapuy, Michael R. McKeown, et al. · Cancer Cell · 733
PDF
Targetable genetic features of primary testicular and primary central nervous system lymphomas
2015 · Bjoern Chapuy, Margaretha G. M. Roemer, et al. · Blood · 585
PDF
PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma
2017 · Lakshmi Nayak, Fabio M. Iwamoto, et al. · Blood · 455
PDF
Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma
2018 · Margaretha G.M. Roemer, Robert A. Redd, et al. · Journal of Clinical Oncology · 364
PDF
Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study
2019 · Stephen M. Ansell, Monique C. Minnema, et al. · Journal of Clinical Oncology · 353
Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma
2017 · Christopher D. Carey, Daniel Gusenleitner, et al. · Blood · 323
PDF
Classical Hodgkin Lymphoma with Reduced β2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status
2016 · Margaretha G.M. Roemer, Ranjana H. Advani, et al. · Cancer Immunology Research · 189
Expression of Programmed Cell Death 1 Ligand 2 (PD-L2) Is a Distinguishing Feature of Primary Mediastinal (Thymic) Large B-cell Lymphoma and Associated With PDCD1LG2 Copy Gain
2014 · Min Shi, Margaretha G.M. Roemer, et al. · The American Journal of Surgical Pathology · 155
Genetic Basis for PD-L1 Expression in Squamous Cell Carcinomas of the Cervix and Vulva
2016 · Brooke E. Howitt, Heather H. Sun, et al. · JAMA Oncology · 137
PDF
PD-L1 and PD-L2 Expression in Cervical Cancer: Regulation and Biomarker Potential
2020 · Jossie Rotman, Leontine A. S. den Otter, et al. · Frontiers in Immunology · 109
PDF
Clinical Validation of Whole Genome Sequencing for Cancer Diagnostics
2021 · Paul Roepman, Ewart de Bruijn, et al. · Journal of Molecular Diagnostics · 90
PDF
Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease
2016 · Bjoern Chapuy, Hongwei Cheng, et al. · Blood · 89
Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment
2021 · Hilma J. van der Horst, A. Vera de Jonge, et al. · Blood Cancer Journal · 86
PDF
PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome
2015 · Margaretha GM Roemer, Ranjana H Advani, et al. · Blood · 85
In-depth cell-free DNA sequencing reveals genomic landscape of Hodgkin’s lymphoma and facilitates ultrasensitive residual disease detection
2021 · Sophia Sobesky, Laman Mammadova, et al. · Med · 80
PDF
Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma
2020 · Gabriel K. Griffin, Jason L. Weirather, et al. · Blood · 60
PDF
Chromosome 20 loss is characteristic of breast implant–associated anaplastic large cell lymphoma
2020 · G. Tjitske Los-de Vries, Mintsje de Boer, et al. · Blood · 56
PDF
A multi-platform reference for somatic structural variation detection
2022 · Jose Espejo Valle-Inclan, Nicolle J.M. Besselink, et al. · Cell Genomics · 51
PDF
B-Cell and Classical Hodgkin Lymphomas Associated With Immunodeficiency
2016 · Daphne de Jong, Margaretha G. M. Roemer, et al. · American Journal of Clinical Pathology · 46
PDF
Extracellular vesicle miRNA predict FDG‐PET status in patients with classical Hodgkin Lymphoma
2021 · Esther E. E. Drees, Margaretha G. M. Roemer, et al. · Journal of Extracellular Vesicles · 39
PDF
Aggressive genomic features in clinically indolent primary HHV8-negative effusion-based lymphoma
2018 · Matias Mendeville, Margaretha G. M. Roemer, et al. · Blood · 36
Works count: 111
Citation count: 8,938
H-index: 29
I10-index: 36
Year
Topic
Type